# A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer

> **NCT00381095** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 152 (actual)

## Conditions studied

- Bone Neoplasms
- Pain, Intractable
- Cancer

## Interventions

- **DRUG:** Pregabalin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00381095
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 152 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2021-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381095, "A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00381095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*